These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1827 related articles for article (PubMed ID: 23808982)

  • 1. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    ; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
    N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban for extended treatment of venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
    N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
    Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
    N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
    Lassen MR; Gallus A; Raskob GE; Pineo G; Chen D; Ramirez LM;
    N Engl J Med; 2010 Dec; 363(26):2487-98. PubMed ID: 21175312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Huang J; Cao Y; Liao C; Wu L; Gao F
    Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.